Who are ALKS 8700's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperidone high dose, Quetiapine 600mg, olanzapine + fluoxetine, aripiprazole (Abilify), Valium + Akineton + Dehydrobenzperidol + Atropine sulfate, Cabergoline (Dopamine Agonist).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alks-8700.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ALKS 8700 — Competitive Intelligence Brief

ALKS 8700 (ALKS 8700) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antipsychotic combination (long-acting injectable). Area: Psychiatry/Neurology.

phase 3 Antipsychotic combination (long-acting injectable) Dopamine D2 receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ALKS 8700 (ALKS 8700) — Biogen. ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ALKS 8700 TARGET	ALKS 8700	Biogen	phase 3	Antipsychotic combination (long-acting injectable)	Dopamine D2 receptor
Risperidone high dose	Risperidone high dose	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Quetiapine 600mg	Quetiapine 600mg	AstraZeneca	marketed	atypical antipsychotic	["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
olanzapine + fluoxetine	olanzapine + fluoxetine	University of Florida	marketed	Atypical antipsychotic + SSRI combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)
aripiprazole (Abilify)	aripiprazole (Abilify)	Massachusetts General Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist)
Valium + Akineton + Dehydrobenzperidol + Atropine sulfate	Valium + Akineton + Dehydrobenzperidol + Atropine sulfate	Universitaire Ziekenhuizen KU Leuven	marketed	Combination sedative-antipsychotic	GABA-A receptor, dopamine D2 receptor, muscarinic acetylcholine receptor
Cabergoline (Dopamine Agonist)	Cabergoline (Dopamine Agonist)	University Hospital, Basel, Switzerland	marketed	Dopamine agonist	Dopamine D2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antipsychotic combination (long-acting injectable) class)

Biogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALKS 8700 — Competitive Intelligence Brief. https://druglandscape.com/ci/alks-8700. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab